Clinical Scorecard: Utilizing Quantitative MRI and Biomarkers for Identifying and Assessing Metabolic Dysfunction-Related Steatotic Liver Disease

At a Glance

Key Highlights

• MASLD affects approximately 30% of adults worldwide and increases risk of cirrhosis and hepatocellular carcinoma.
• Quantitative MRI techniques (PDFF, MRE, DWI, cT1 mapping) provide non-invasive assessment of steatosis, inflammation, and fibrosis.
• Combining qMRI with laboratory biomarkers and anthropometric measures improves diagnostic accuracy for staging MASLD.

Guideline-Based Recommendations

Diagnosis

• Use liver biopsy as reference standard but consider non-invasive qMRI techniques due to biopsy limitations.
• Quantify hepatic steatosis with MRI-proton density fat fraction (PDFF).
• Assess inflammation and fibrosis using MR elastography (MRE), T1 mapping, and diffusion-weighted MRI (DWI).
• Combine qMRI parameters with clinical and laboratory biomarkers (e.g., AST, waist circumference) for improved diagnosis.

Management

• Identify patients with fibrotic MASH (fibro-MASH) and advanced fibrosis (≥ F3) for targeted interventions.
• Use non-invasive scores such as MR-MASH, MAST, and MEFIB to stratify disease severity and guide management.

Monitoring & Follow-up

• Employ serial qMRI assessments to non-invasively monitor disease progression and response to therapy.
• Incorporate laboratory biomarkers and elastography measurements in follow-up evaluations.

Risks

• Recognize that invasive liver biopsy carries risks including sampling error and interobserver variability.
• Consider that advanced fibrosis and fibro-MASH stages are associated with increased morbidity and mortality.

Patient & Prescribing Data

Adults with metabolic risk factors and evidence of hepatic steatosis

Non-invasive qMRI combined with biomarker scores can identify patients at higher risk who may benefit from closer monitoring or therapeutic interventions.

Clinical Best Practices

• Ensure patients fast for at least 4 hours prior to MRI and laboratory assessments to optimize accuracy.
• Use standardized MRI acquisition protocols and experienced operators for ROI placement and data analysis.
• Integrate multiple qMRI parameters with clinical and laboratory data to enhance diagnostic precision.
• Apply validated composite scores (MR-MASH, MAST, MEFIB) to identify patients with significant fibrosis and steatohepatitis.
• Consider non-invasive techniques as alternatives to liver biopsy to reduce procedural risks.

References

• Global prevalence and burden of MASLD
• Definition and spectrum of MASLD
• Limitations of liver biopsy
• MRI techniques for liver assessment
• MR-MASH, MAST and MEFIB scores